Johnson & Johnson highlights psoriasis candidate with long-term data [Seeking Alpha]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Seeking Alpha
Last month, citing previewed data, the pharma giant said JNJ-2113, an oral IL-23 receptor blocker, reached all the primary and secondary endpoints in FRONTIER 1 in adults with moderate-to-severe plaque psoriasis (PsO). Announcing the first readout from the FRONTIER 2 trial, in which all patients received JNJ-2113 after the first 16 weeks in FRONTIER 1, J&J ( JNJ ) said results through week 52 were consistent with those from the prior study. There were no new safety signals, and the drug's tolerability profile was in line with findings from FRONTIER 1. The company's pivotal Phase 3 ICONIC for the candidate in PsO is currently underway in partnership with Protagonist Therapeutics ( NASDAQ: PTGX Noting that FRONTIER 1 and FRONTIER 2 suggested the potential of JNJ-2113 in other IL-23-mediated diseases, J&J ( JNJ ) said it has begun a Phase 2b trial to evaluate the candidate in ulcerative colitis, a bowel disorder. Recommended For You Recommended For You Related Stocks Tre
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Turnstone Biologics Appoints William Waddill to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Hemochromatosis Pipeline Insight Report 2024, Featuring Protagonist Therapeutics, Sirnaomics and Bond Biosciences [Yahoo! Finance]Yahoo! Finance
- Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135% [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataAccesswire
PTGX
Earnings
- 8/3/23 - Miss
PTGX
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- PTGX's page on the SEC website